Is PROCEPT BioRobotics (PRCT) Prioritizing Growth Over Profitability With Its Latest Revenue Projections?

• PROCEPT BioRobotics Corporation recently reported its third quarter 2025 results, showing US$83.33 million in revenue and a net loss of US$21.41 million, alongside reaffirmed 2025 revenue guidance and new 2026 projections calling for continued double-digit revenue growth.
• While operating losses continue, the company highlighted strong U.S. and international sales growth, as well as early positive impacts from commercial initiatives and new account launches.
• We'll examine how PROCEPT's maintained growth outlook and robust procedure volumes are shaping the company’s broader investment narrative.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, an investor needs conviction in the long-term adoption of Aquablation and the HYDROS platform as a standard treatment, while accepting persistent operating losses as the company presses for market expansion. The latest results reinforce the most important short-term catalyst, procedure volume growth, showing robust sales despite ongoing losses, but the report does not materially change the biggest current risk: heavy reliance on one platform in a competitive market.

Among recent announcements, the reaffirmation of 2025 revenue guidance and the introduction of a 2026 forecast for continued double-digit growth directly tie to procedure growth, a key catalyst. These targets support management's optimism that sales momentum from new commercial initiatives and hospital launches can outweigh profitability concerns, at least for now.

By contrast, investors should be alert to how PROCEPT’s reliance on the HYDROS/Aquablation platform leaves it exposed if a more advanced or cost-effective rival technology emerges...

Read the full narrative on PROCEPT BioRobotics (it's free!)

PROCEPT BioRobotics' outlook projects $563.8 million in revenue and $70.4 million in earnings by 2028. This scenario assumes a 27.0% annual revenue growth and a $154.5 million improvement in earnings from the current level of -$84.1 million.

Uncover how PROCEPT BioRobotics' forecasts yield a $60.90 fair value, a 95% upside to its current price.

Exploring Other Perspectives

Fair value estimates from seven Simply Wall St Community members range from US$27.49 to US$85 per share, reflecting a broad spectrum of outlooks on PROCEPT’s potential. With procedure volume growth in focus, opinions on long-term adoption and competition diverge, explore these perspectives to see how others weigh the risks and rewards.

Explore 7 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth 12% less than the current price!

Build Your Own PROCEPT BioRobotics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com